

COSTEM 2019 Scientific Program
as of October 16, 2019

Thursday, October 24, 2019 Hall B (-1st floor)	
15:30-17:00	<i>CAR T-cell therapy in DLBCL – opportunities and challenges</i> <i>Gilead/Kite industry-supported Symposium</i>
17:00-17:30	<i>Coffee Break</i>
17:30-18:30	<i>Extracorporeal photopheresis: Immunomodulation and combinational therapies</i> <i>Mallinckrodt industry-supported Symposium</i>
18:30	Welcome Reception in the Hotel Lobby

Friday, October 25, 2019			
	Hall A (Ground floor)		
08:00-09:00	<i>Treating NHL and MM in the age of CAR T</i> <i>Celgene industry-supported Symposium</i>		
09:00-09:15	Short Break		
09:15-10:45	Opening Session		
09:15-09:25	Welcome note: Nicolaus Kröger , Germany; Arnon Nagler , Israel		
09:25-10:05	Controversy: Are haploidentical donors – the alternative donors of choice? Moderator: Nicolaus Kröger , Germany		
09:25-09:40	Yes: Leonido Luznik , USA		
09:40-09:55	No: Arnon Nagler , Israel		
09:55-10:05	Discussion		
10:05-10:45	Controversy: Can CAR T cells replace autologous stem cell transplantation in DLBCL? Moderator: Arnon Nagler , Israel		
10:05-10:20	Yes: Stephen J. Schuster , USA		
10:20-10:35	No: Michael R. Bishop , USA		
10:35-10:45	Discussion		
10:45-11:15	Coffee Break, Poster Viewing and Visit Exhibition		
	Hall A (Ground floor)		Hall B (-1st floor)
11:15-12:45	Session 2: Acute lymphoblastic leukemia	11:15-12:45	Session 3: Alternative donor
11:15-12:00	Controversy: How to bridge to transplant in relapsed ALL? Moderator: David Marks , UK	11:15-12:00	Controversy: Can post-transplant cyclophosphamide be used as GVHD prophylaxis as well in HLA-identical sibling as in MUD transplantation? Moderator: Annalisa Ruggeri , France
11:15-11:25	Pro: Blinatumomab: Nicola Gökbuget , Germany	11:15-11:30	Yes: Andrea Bacigalupo , Italy

11:25-11:35 11:35-11:45 11:45-12:00	Pro: Inotuzumab: Matthias Stelljes , Germany Pro: CAR T cells: Peihua Lu , China Discussion	11:30-11:45 11:45-12:00	No: Luca Castagna , France Discussion
12:00-12:45 12:00-12:10 12:10-12:20 12:20-12:30 12:30-12:45	Controversy: How to cure Ph+ ALL in adults Moderator: Dieter Hoelzer , Germany By allogeneic SCT: David Marks , UK By chemotherapy plus TKI: Renato Bassan , Italy By CAR T cells: Peter Bader , Germany Discussion	12:00-12:45 12:00-12:15 12:15-12:30 12:30-12:45	Controversy: Can ATG overcome negative outcome of mismatched unrelated donor? Moderator: Andrea Bacigalupo , Italy Yes: Jürgen Finke , Germany No: Robert J. Soiffer , USA Discussion
12:45-13:15	Lunch Pick-up, Poster Viewing and Visit Exhibition		
13:15-14:15	Redefining the role of cell therapies in allogeneic HSCT Kiadis industry-supported Lunch Symposium – Hall A		
14:15-14:30	Short Break		
	Hall A		Hall B
14:30-16:00	Session 4: Acute myeloid leukemia	14:30-16:00	Session 5: Cord blood transplantation
14:30-15:15 14:30-14:45 14:45-15:00 15:00-15:15	Controversy: Myeloablative conditioning regimen should be preferred in all fit AML patients Moderator: Charles Craddock , UK Yes: Bart Lee Scott , USA No: Avichai Shimoni , Israel Discussion	14:30-15:15 14:30-14:45 14:45-15:00 15:00-15:15	Controversy: Is double cord blood transplantation out? Moderator: Annalisa Ruggeri , France Yes: Éliane Gluckman , France No: Vanderson Rocha , Brazil Discussion
15:15-16:00 15:15-15:30 15:30-15:45 15:45-16:00	Controversy: Is MRD monitoring prior to allograft standard in AML? Moderator: Alessandro Rambaldi , Italy Yes: Michael Heuser , Germany No: Jan Cornelissen , Netherlands Discussion	15:15-16:00 15:15-15:30 15:30-15:45 15:45-16:00	Controversy: Is endothelial protection effective for GVHD, VOD, and TMA? Moderator: Vanderson Rocha , Brazil Yes: Olaf Penack , Germany No: Mohamad Mohty , France Discussion
16:00-16:30	Coffee Break, Poster Viewing and Visit Exhibition		
16:30-17:30	Paving the way to transplant in ALL Pfizer industry-supported Symposium – Hall A		
17:30-17:45	Short Break		
	Hall A		Hall B
17:45-19:15	Session 6: MDS	17:45-19:15	Session 7: Haplo-identical donor issues
17:45-18:30 17:45-17:55 17:55-18:05	Controversy: How to prepare MDS-EB prior to transplantation Moderator: Wael Saber , USA By hypomethylating agents: Marie Robin , France By sequential chemotherapy: Charles Craddock , UK	17:45-18:30 17:45-18:00 18:00-18:15	Controversy: Is bone marrow the preferred stem cell source in haplo-SCT settings post cyclophosphamide? Moderator: Jan Cornelissen , Netherlands Yes: Stefan Ciurea , USA No: Annalisa Ruggeri , France

18:05-18:15 18:15-18:30	By no intervention: Ibrahim Yakoub-Agha , France Discussion	18:15-18:30	Discussion
18:30-19:15 18:30-18:45 18:45-19:00 19:00-19:15	Controversy: Should MDS patients with complex karyotype and p53 mutation receive an allograft? Moderator: Avichai Shimoni , Israel Yes: Wael Saber , USA No: Alessandro Rambaldi , Italy Discussion	18:30-19:15 18:30-18:45 18:45-19:00 19:00-19:15	Controversy: What is the optimal GVHD prophylaxis in T-cell repleted haploidentical transplantation? Moderator: Stefan Ciurea , USA ATG: He Huang , China Post Cy: Christopher Kanakry , USA Discussion

Saturday, October 26, 2019			
	Hall A (Ground floor)		Hall B (Ground floor)
08:00-09:30	Session 8: Aplastic anemia	08:00-09:30	Session 9: Graft-versus-host disease
08:00-08:45 08:00-08:15 08:15-08:30 08:30-08:45	Controversy: Is upfront MUD justified for SAA in 2019? Moderator: Régis Peffault de Latour , France Yes: Carlo Dufour , Italy No: Antonio Risitano , Italy Discussion	08:00-08:45 08:00-08:15 08:15-08:30 08:30-08:45	Controversy: Is ruxolitinib the new standard for steroid refractory acute and chronic GVHD? Moderator: Hildegard Greinix , Austria Yes: Robert Zeiser , Germany No: Steven Pavletic , USA Discussion
08:45-09:30 08:45-09:00 09:00-09:15 09:15-09:30	Controversy: Is haplo better than cord as alternative donor source in SAA? Moderator: Carlo Dufour , Italy Yes: Rainer Storb , USA No: Régis Peffault de Latour , France Discussion	08:45-09:30 08:45-09:00 09:00-09:15 09:15-09:30	Controversy: Is ATG standard GVHD prophylaxis after HLA-identical sibling transplantation? Moderator: Steven Pavletic , USA Yes: Francesca Bonifazi , Italy No: Hildegard Greinix , Austria Discussion
09:30-10:00	Coffee Break, Poster Viewing and Visit Exhibition		
10:00-11:00	Letermovir with an AI-recommendation in CMV-prophylaxis: How far can we go from here? MSD industry-supported Symposium – Hall A		
11:00-11:15	Short Break		
	Hall A		Hall B
11:15-12:45	Session 10: Multiple myeloma	11:15-12:45	Session 11: Complications
11:15-12:00 11:15-11:30 11:30-11:45 11:45-12:00	Controversy: Is CAR T cell therapy becoming the new standard for relapsed MM? Moderator: Michele Cavo , Italy Yes: Hermann Einsele , Germany No: Philippe Moreau , France Discussion	11:15-12:00 11:15-11:30 11:30-11:45 11:45-12:00	Controversy: How can the microbiome be better targeted? Moderator: Robert Zeiser , Germany By fecal transplantation: Francis Ayuk , Germany By antibiotic: Ernst Holler , Germany Discussion

12:00-12:45	Controversy: Is tandem autologous SCT out for newly diagnosed MM? Moderator: Philippe Moreau , France Yes: Sergio A. Giralt , USA No: Michele Cavo , Italy Discussion	12:00-12:45	Controversy: Can third party CMV-specific T-cells replace drug therapy? Moderator: Jan Styczynski , Poland Yes: Catherine M. Bollard , USA No: Per Ljungman , Sweden Discussion
12:00-12:15		12:00-12:15	
12:15-12:30		12:15-12:30	
12:30-12:45		12:30-12:45	
12:45-13:15	Lunch Pick-up, Poster Viewing and Visit Exhibition		
13:15-14:15	Plerixafor, 10 years after approval: Time to abandon chemotherapy for stem cell mobilization? Sanofi Genzyme industry-supported Lunch Symposium – Hall A		
14:15-14:30	Short Break		
	Hall A		Hall B
14:30-16:00	Session 12: NHL and Hodgkin's disease	14:30-16:00	Session 13: Relapse prevention
14:30-15:15	Controversy: Can CAR T cells replace allo SCT in RR DLBCL? Moderator: Anna Sureda , Spain Yes: Ulrich Dührsen , Germany No: Bertram Glaß , Germany Discussion	14:30-15:15	Controversy: Are hypomethylating agents useful to prevent relapse in AML and MDS? Moderator: Ibrahim Yakoub-Agha , France Yes: Marcos de Lima , USA No: Jakob Passweg , Switzerland Discussion
14:30-14:45		14:30-14:45	
14:45-15:00		14:45-15:00	
15:00-15:15		15:00-15:15	
15:15-16:00	Controversy: Is a haploidentical donor the donor of choice in relapsed Hodgkin's disease? Moderator: Michael R. Bishop , USA Yes: Anna Sureda , Spain No: Stephen Robinson , UK Discussion	15:15-16:00	Controversy: Are suicide modified DLIs better than naïve DLIs to prevent relapse? Moderator: Jakob Passweg , Switzerland Yes: Fabio Ciceri , Italy No: Hans-Jochem Kolb , Germany Discussion
15:15-15:30		15:15-15:30	
15:30-15:45		15:30-15:45	
15:45-16:00		15:45-16:00	
16:00-16:30	Coffee Break, Poster Viewing and Visit Exhibition		
16:30-17:30	Transplantation in an evolving therapy landscape Novartis industry-supported Symposium – Hall A		
17:30-17:45	Short Break		
	Hall A		Hall B
17:45-19:15	Session 14: Autoimmune disease and CAR T cells	17:45-19:15	Session 15: Myeloma (II) / NHL
17:45-18:30	Controversy: Is autologous SCT for R/R MS becoming a standard therapy? Moderator: Tobias Alexander , Germany Yes: John Snowden , UK No: Tamir Ben-Hur , Israel Discussion	17:45-18:30	Controversy: Should maintenance therapy after autograft be limited? Moderator: Sergio A. Giralt , USA Yes: Hartmut Goldschmidt , Germany No: Philip L. McCarthy , USA Discussion
17:45-18:00		17:45-18:00	
18:00-18:15		18:00-18:15	
18:15-18:30		18:15-18:30	
18:30-19:15	Controversy: Can CAR T cell response be predicted? Moderator: Nicolaus Kröger , Germany	18:30-19:15	Controversy: Is autologous or allogeneic SCT the standard for peripheral T-cell lymphoma?

18:30-18:45 18:45-19:00 19:00-19:15	Yes, by biomarker: He Huang , China Yes, by microbiome: Marcel van den Brink , USA Discussion	18:30-18:45 18:45-19:00 19:00-19:15	Moderator: Stephen Robinson , UK Pro auto: Francesco D'Amore , Denmark Pro allo: Norbert Schmitz , Germany Discussion
19:15-20:15	<i>COSTEM Poster Walk and Awards</i> <i>(1st floor foyer)</i>		

Sunday, October 27, 2019 Hall A (Ground floor)	
08:30-10:00	Session 16: NK-cell therapy
08:30-09:15	Controversy: Are NK-CAR-cells the future of NK-cell therapy? Moderator: Daniel Weisdorf , USA
08:30-08:45	Yes: Katy Rezvani , USA
08:45-09:00	No: Jeffrey Miller , USA
09:00-09:15	Discussion
09:15-10:00	Controversy: Is KIR-typing relevant for donor selection? Moderator: Jeffrey Miller , USA
09:15-09:30	Yes: Daniel Weisdorf , USA
09:30-09:45	No: Johannes Schetelig , Germany
09:45-10:00	Discussion
10:00-10:30	<i>Coffee Break</i>
10:30-12:00	Session 17: Inborn errors
10:30-11:15	Controversy: Is haplo SCT the best curative option for sickle cell disease? Moderator: Arjan Lankester , Netherlands
10:30-10:45	Yes: Selim Corbacioglu , Germany
10:45-11:00	No: Miguel Abboud , Lebanon
11:00-11:15	Discussion
11:15-12:00	Controversy: Best curative option for thalassemia in 2019? Moderator: Selim Corbacioglu , Germany
11:15-11:30	Gene therapy: Sarah Markt , Italy
11:30-11:45	Allogeneic SCT: Arjan Lankester , Netherlands
11:45-12:00	Discussion
12:00	Closing remarks Nicolaus Kröger , Germany; Arnon Nagler , Israel